KaNDy Therapeutics

About:

KaNDy Therapeutics is a clinical-stage company focused on optimizing the potential of NT-814.

Website: http://www.kandytherapeutics.com

Top Investors: OrbiMed, Forbion Capital Partners, Longitude Capital, Advent Life Sciences, Fountain Healthcare Partners

Description:

KaNDy Therapeutics is a provider of bio-technical research and development services intended to offer treatment for common, chronic debilitating female sex hormone-related conditions. The company's services offer non-hormonal therapy to treat moderate to severe post-menopausal vasomotor symptoms, enabling patients to receive treatment and reduce symptoms of hormone-related conditions.

Total Funding Amount:

25M GBP

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Stevenage, Herefordshire, United Kingdom

Founded Date:

2017-01-01

Contact Email:

info(AT)kandytherapeutics.com

Founders:

Mary Kerr, Mike Trower

Number of Employees:

11-50

Last Funding Date:

2018-08-29

IPO Status:

Private

Industries: